TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (NCT07223203)
TRITON-PN: A Phase 3, Global, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy (hATTR-PN)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed * Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels
Who can join: Review the eligibility criteria below.
Location: Clinical Trial Site — Aurora, Colorado
Age range: 18 Years to 85 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (48 Sites)
Showing the first 25 of 48 sites.
- Clinical Trial Site — Aurora, Colorado
- Clinical Trial Site — Chicago, Illinois
- Clinical Trial Site — Baltimore, Maryland
- Clinical Trial Site — Boston, Massachusetts
- Clinical Trial Site — Rochester, Minnesota
- Clinical Trial Site — New York, New York
- Clinical Trial Site — Chapel Hill, North Carolina
- Clinical Trial Site — Nashville, Tennessee
- Clinical Trial Site — Dallas, Texas
- Clinical Trial Site — Houston, Texas
- Clinical Trial Site — Darlinghurst,
- Clinical Trial Site — Woolloongabba,
- Clinical Trial Site — Ribeirão Preto,
- Clinical Trial Site — São Paulo,
- Clinical Trial Site — Vancouver,
- Clinical Trial Site — Égkomi,
- Clinical Trial Site — Créteil,
- Clinical Trial Site — Le Kremlin-Bicêtre,
- Clinical Trial Site — Marseille,
- Clinical Trial Site — Berlin,
- Clinical Trial Site — Heidelberg,
- Clinical Trial Site — Münster,
- Clinical Trial Site — Athens,
- Clinical Trial Site — Heraklion,
- Clinical Trial Site — Florence,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.